Tonix Pharmaceuticals (TNXP) Expected to Post Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) is projected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Tonix Pharmaceuticals to post earnings of ($2.3885) per share and revenue of $16.32 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, August 10th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.64) by $0.20. Tonix Pharmaceuticals had a negative return on equity of 68.99% and a negative net margin of 548.64%. The firm had revenue of $13.54 million during the quarter, compared to the consensus estimate of $7.72 million. On average, analysts expect Tonix Pharmaceuticals to post ($9.90) EPS for the current fiscal year and ($6.62) EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

TNXP stock opened at $5.10 on Monday. The stock has a 50-day moving average price of $9.53 and a 200-day moving average price of $12.50. Tonix Pharmaceuticals has a 1-year low of $4.96 and a 1-year high of $20.56. The firm has a market cap of $87.47 million, a PE ratio of -0.39 and a beta of 1.90.

Wall Street Analyst Weigh In

Several brokerages recently commented on TNXP. Wall Street Zen upgraded Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, October 4th. Raymond James Financial reiterated a “strong-buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, October 20th. Canaccord Genuity Group began coverage on Tonix Pharmaceuticals in a research note on Monday, October 26th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Monday, October 26th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tonix Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $22.33.

Insider Buying and Selling

In other news, CEO Seth Lederman purchased 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $13.79 per share, with a total value of $27,580.00. Following the purchase, the chief executive officer owned 11,005 shares in the company, valued at $151,758.95. This represents a 22.21% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is owned by insiders.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving the central nervous system, immunology and infectious diseases. The company’s research programs are designed to address disorders with significant unmet medical needs, including chronic pain, neuropsychiatric conditions and infectious diseases.

Tonix’s pipeline has included TNX-102 SL, an investigational sublingual formulation of cyclobenzaprine being studied for fibromyalgia and other pain-related conditions.